ProCE Banner Activity

PANTHER: Randomized Phase III Trial of First-line Pevonedistat + Azacitidine vs Azacitidine in Higher-Risk MDS/CMML or AML With 20% to 30% Marrow Blasts

Slideset Download
Conference Coverage
Pevonedistat plus azacitidine did not improve EFS compared with azacitidine alone in patients with higher-risk MDS/CMML or low-blast AML.

Released: December 20, 2021

Expiration: December 19, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation